PharmaCyte Biotech shares surge 18.07% premarket as CEO and director buy shares, boost cash reserves to $20M.

PharmaCyte Biotech surged 18.07% in premarket trading following two key developments: CEO Joshua Silverman’s $80,476 purchase of 100,000 shares over three days, signaling strong management confidence, and the company’s successful monetization of its stake in Femasys Inc., which boosted cash and marketable securities to $20 million from $13.3 million. The CEO’s direct ownership now stands at 416,250 shares, while the Femasys exit underscores a strategic focus on capital efficiency and risk mitigation. Additional insider buying by director Jonathan Schechter, who acquired 60,000 shares totaling $48,232, further reinforced positive sentiment ahead of the premarket rally.